Диссертация (1140240), страница 18
Текст из файла (страница 18)
Dermatol. Veneroel.Leprol. – 2007. - Vol. 73,N 3. – P. 149-156.153.Shen Z., Gao T.W., Chen L., Yang L., Wang Y.C., Sun L.C., Li C.Y.,Xiao Y., Liu Y.F. Optimal frequency of treatment with the 308-nm excimer laserfor vitiligo on the face and neck // Photomed Laser Surg. 2007 (5): 418-27.154.Shin J.W., Nam K.M., Choi H.R., Huh S.Y., Kim S.W., Youn S.W.,Huh C.H., Park K.C.
Erythrocyte malondialdehyde and glutathione levels invitiligopatients.//AnnDermatol.2010Aug;22(3):279-83.doi:10.5021/ad.2010.22.3.279. Epub 2010 Aug 5.155.Spencer J.M., Hadi S.M. The excimer lasers.J Drugs Dermatol. 2004;3(5): 522—525.156.Stromberg S., Bjorklund M.G., Asplund A. et al.
Transcriptionalprofiling of melanocytes from patients with vitiligo vulgaris // Pigment. CellMelan.Res. – 2008. - Vol. 21, N 2. – P. 161-171.157.Sun X., Xu A., Wei X., Ouyang J., Lu L., Chen M., Zhang D. Geneticepidemiology of vitiligo: a study of 815 probands and their families from southChina. Int. J. Dermatol. 2006, 45, 1176-1181.158.Taieb A., Picardo M. Epidemiology, definitions and classification. In:Vitiligo, Springer Publisher, Berlin-Heidelberg, 2010, 13-24159.Taneja A., Trehan M., Taylor C.R. 308-nm excimer laser for thetreatment of localized vitiligo. // Int. J.
Dermatol. 2003. - V.42, n.8. -P.658-662.160.Tham S.N., Gange R.W., Parrish J.A. Ultraviolet-B treatment ofpsoriasis in patients with concomitant vitiligo.// Arch Dermatol. 1987Jan;123(1):26-7.161.Tjioe M., Gerritsen MJ, Juhlin L, van de Kerkhof PC. Treatment ofvitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect ofaddition of folic acid and vitamin B12.Acta Derm Venereol.2002; 82 (6):485.162.Toker S.C., Sarycaoglu H., Karadogan S.K., Mistik R., Baskan E.B.,Tunaly S. Is there any relation between vitiligo and cytomegalovirus?// J Eur Acad114Dermatol Venereol. 2007 Jan;21(1):141-2.163.Trehan M., Taylor C.R.
Low-dose excimer 308 nm laser for thetreatment of oral lichen planus. //Arch. Dermatol. 2004; 140 (4): 415—420164.Valkova S, Trashlieva M, Christova P. Treatment of vitiligo with localkhellin and UVA: comparison with systemic PUVA.Clin Exp Dermatol. 2004;29(2): 180-4165.Van Geel N., Ongenae K., De Mil M. et al. Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions forrepigmenting vitiligo // Arch. Dermatol. – 2004. – Vol. 140.
– P. 1203-1208.166.Welsh O., Herz-Ruelas M.E., Gomez M., Ocampo-Candiani J.Therapeutic evaluation of UVB-targeted phototherapy in vitiligo that affects lessthan 10% of the body surface area. Int J Dermatol 2009; 48: 529—534.167.Westerhof W., Nievweboer-Krobotova L. Treatment of vitiligo withUVB radiation with topical psoralen plus UVA. //Arch Dermatol. 1997; 133:15251528.168.Wijngaard R.M., Wankowicz-Kalinska A., Le Poole C., Tigges B.,Westerhof W., Das P. Local immune response in skin of generalized vitiligopatients. Destruction of melanocytes is associated with the prominent presence ofCLA+ T cells at the perilesional site.// Lab Invest. 2000 Aug;80(8):1299-309.169.Yones S.S., Palmer R.A., Garibaldinos T.M., Hawk J.L.
Randomizeddouble-blind trial of treatment of vitiligo: Efficacy of psoralen-UV-A therapy vsNarrowband-UV-B therapy. Arch Dermatol 2007; 143: 578—584170.Yu H.S., Chang K.L., Yu C.L., Li H.F., Wu M.T., Wu C.S., Wu C.S.Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release byperipheral mononuclear cells in patients with active vitiligo.// J Invest Dermatol.1997 Apr;108(4):527-9.115.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
